Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop

P. Lorigan; A. M.M. Eggermont

doi:10.1093/annonc/mdz182

Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop

Onderzoeksoutput: Bijdrage aan tijdschrift › Editoriaal

14 Citaten (Scopus)

Originele taal-2	Engels
Artikelnummer	mdz182
Pagina's (van-tot)	1038-1040
Aantal pagina's	3
Tijdschrift	Annals of Oncology
Volume	30
Nummer van het tijdschrift	7
DOI's	https://doi.org/10.1093/annonc/mdz182
Status	Gepubliceerd - 1 jul. 2019
Extern gepubliceerd	Ja

Toegang tot document

10.1093/annonc/mdz182

Citeer dit

@article{bc1ba0e2e0e24bed932abaf0efa63611,

title = "Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop",

author = "P. Lorigan and Eggermont, \{A. M.M.\}",

note = "Funding Information: PL has been paid advisor/speaker for BMS, MSD, Novartis, Amgen, Roche, Neracare, Pierre Fabre, received research funding from BMS and received support for travel MSD, BMS. AMME received honoraria for SAB or IDMC from BMS, CatalYm, CellDex, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, MSD, Novartis, Pfizer, Polynoma, Sanofi, Sellas, SkylineDx and received speaker fees from MSD, Novartis. Stock Options: RiverD, SkylineDX.",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz182",

language = "English",

volume = "30",

pages = "1038--1040",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - Anti-PD1 treatment of advanced melanoma

T2 - development of criteria for a safe stop

AU - Lorigan, P.

AU - Eggermont, A. M.M.

N1 - Funding Information: PL has been paid advisor/speaker for BMS, MSD, Novartis, Amgen, Roche, Neracare, Pierre Fabre, received research funding from BMS and received support for travel MSD, BMS. AMME received honoraria for SAB or IDMC from BMS, CatalYm, CellDex, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, MSD, Novartis, Pfizer, Polynoma, Sanofi, Sellas, SkylineDx and received speaker fees from MSD, Novartis. Stock Options: RiverD, SkylineDX.

PY - 2019/7/1

Y1 - 2019/7/1

UR - https://www.scopus.com/pages/publications/85071190878

U2 - 10.1093/annonc/mdz182

DO - 10.1093/annonc/mdz182

M3 - Editorial

C2 - 31218362

AN - SCOPUS:85071190878

SN - 0923-7534

VL - 30

SP - 1038

EP - 1040

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

M1 - mdz182

ER -